Initially diagnosed with BRAF V600E-mutated melanoma, he received Dabrafenib and Trametinib...Despite initial treatment with Triptorelin, Docetaxel, and Abiraterone, disease progression occurred...This case illustrates the value of precision medicine and the role of liquid biopsy in guiding immunotherapy decisions for complex oncological cases. It supports the relevance of molecular profiling in selecting effective treatments beyond standard indications.

5 days ago

Journal • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset)

TP53 mutation • BRAF V600E • TMB-H • BRAF V600 • ATM mutation

Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • docetaxel • abiraterone acetate • triptorelin

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)

P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028

6 days ago

Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)

carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial). (PubMed, Prostate Cancer Prostatic Dis)

This study clarifies the clinical relevance of cytoplasmic AR-V7 in circulating tumor cells from men with metastatic castration-resistant prostate cancer. While nuclear-localized AR-V7 predicts extremely poor response, PFS, and overall survival with AR pathway inhibitors, cytoplasmic AR-V7 expands the definition of AR-V7-positive status and identifies patients with equally poor PFS and intermediate response and overall survival outcomes. Assessing both nuclear and cytoplasmic AR-V7 fractions may thus improve risk stratification heterogeneity and could better guide poor-risk ARPI treatment decisions by avoiding ineffective ARPI treatment, helping personalize therapy, and improving outcomes in men with mCRPC.

6 days ago

Journal

AR (Androgen receptor)

AR splice variant 7

CELLSEARCH®

Xtandi (enzalutamide) • abiraterone acetate

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer (clinicaltrials.gov)

P1, N=300, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> May 2028 | Trial primary completion date: Jun 2026 --> Aug 2027

6 days ago

Trial completion date • Trial primary completion date

docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • apalutamide • cetrelimab (JNJ-63723283) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • pasritamig (JNJ-8343)

Double-DARE: A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics (clinicaltrials.gov)

P=N/A, N=1400, Recruiting, Bayer | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> May 2026

7 days ago

Trial completion date • Trial primary completion date • Real-world evidence

docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)

P1/2, N=123, Recruiting, Novartis Pharmaceuticals | N=73 --> 123

7 days ago

Enrollment change • Trial initiation date

Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Targeted inhibition of the CREB1-CtIP axis enhances the efficacy of abiraterone combined with radiotherapy in prostate cancer. (PubMed, Cell Death Dis)

Finally, our in vitro and in vivo experiments indicate that the CREB1 phosphorylation inhibitor 666-15 significantly enhances the therapeutic efficacy of Abi-RT combination therapy. In summary, our study reveals that inhibition of the CREB1-CtIP axis effectively improves the therapeutic outcomes of Abi-RT combination therapy, which may offer a novel clinical strategy for the treatment of prostate cancer.

7 days ago

Journal

HRD (Homologous Recombination Deficiency) • RBBP8 (RB Binding Protein 8, Endonuclease) • CREB1 (CAMP Responsive Element Binding Protein 1)

abiraterone acetate

11d

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov)

P2, N=102, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

11 days ago

Trial completion date • Trial primary completion date

CD4 (CD4 Molecule)

Oncotype DX Genomic Prostate Score® Assay

abiraterone acetate • prednisone • apalutamide

13d

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. (PubMed, J Immunother Cancer)

Olaparib plus durvalumab demonstrated modest activity in HRR-unselected mCRPC, with clinical benefit enriched in BRCA2-variant disease. Integrated ctDNA and peripheral immune analyses support ongoing efforts to refine molecular and immune selection strategies and to better define mechanisms of benefit and resistance for combination approaches in mCRPC.

13 days ago

P2 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker

BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)

Lynparza (olaparib) • Imfinzi (durvalumab) • Xtandi (enzalutamide) • abiraterone acetate

13d

Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study. (PubMed, Clin Cancer Res)

Cabazitaxel and carboplatin followed by abiraterone, together with ADT, was feasible, safe, and efficacious in patients with high-volume mCSPC, and warrants further study in larger randomized trials.

13 days ago

P2 data • Journal

HRD (Homologous Recombination Deficiency)

carboplatin • abiraterone acetate • prednisone • cabazitaxel

14d

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (clinicaltrials.gov)

P2, N=192, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting

14 days ago

Enrollment open

abiraterone acetate • apalutamide • triptorelin • goserelin acetate • AiRuiEn (rezvilutamide)

14d

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (clinicaltrials.gov)

P1/2, N=360, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2030 --> Apr 2031 | Trial primary completion date: Feb 2030 --> Apr 2031

14 days ago

Trial completion date • Trial primary completion date

docetaxel • Xtandi (enzalutamide) • abiraterone acetate • ifinatamab deruxtecan (DS-7300) • opevesostat (MK-5684)